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Abstract
Objective To evaluate the effectiveness of rotavirus vaccination among
young children in Belgium.
Design Prospective case-control study.
SettingRandom sample of 39 Belgian hospitals, February 2008 to June
2010.
Participants 215 children admitted to hospital with rotavirus
gastroenteritis confirmed by polymerase chain reaction and 276 age
and hospital matched controls. All children were of an eligible age to
have received rotavirus vaccination (that is, born after 1 October 2006
and aged ≥14 weeks).
Main outcome measure Vaccination status of children admitted to
hospital with rotavirus gastroenteritis and matched controls.
Results 99 children (48%) admitted with rotavirus gastroenteritis and
244 (91%) controls had received at least one dose of any rotavirus
vaccine (P<0.001). The monovalent rotavirus vaccine accounted for
92% (n=594) of all rotavirus vaccine doses. With hospital admission as
the outcome, the unadjusted effectiveness of two doses of the
monovalent rotavirus vaccine was 90% (95% confidence interval 81%
to 95%) overall, 91% (75% to 97%) in children aged 3-11 months, and
90% (76% to 96%) in those aged ≥12 months. The G2P[4] genotype
accounted for 52% of cases confirmed by polymerase chain reaction
with eligible matched controls. Vaccine effectiveness was 85% (64% to
94%) against G2P[4] and 95% (78% to 99%) against G1P[8]. In 25% of
cases confirmed by polymerase chain reaction with eligible matched
controls, there was reported co-infection with adenovirus, astrovirus
and/or norovirus. Vaccine effectiveness against co-infected cases was
86% (52% to 96%). Effectiveness of at least one dose of any rotavirus
vaccine (intention to vaccinate analysis) was 91% (82% to 95%).
Conclusions Rotavirus vaccination is effective for the prevention of
admission to hospital for rotavirus gastroenteritis among young children
in Belgium, despite the high prevalence of G2P[4] and viral co-infection.
Introduction
Rotavirus is the most common cause of severe acute
gastroenteritis in infants and young children worldwide.1Nearly
every child will have experienced a symptomatic infection
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before the age of 5 years,1 2 with the peak incidence occurring
among children aged 4-23 months.3 4 Although rarely fatal in
high income regions,1 2 rotavirus gastroenteritis places a high
demand on European healthcare systems.5-8 Surveillance studies
have shown that rotavirus accounts for up to two thirds of
admissions to hospital and emergency room visits and one third
of primary care consultations for acute gastroenteritis among
children under 5 years in Europe, with the greatest burden of
disease consistently seen in children aged under 2.6-8 In Belgium,
rotavirus gastroenteritis was estimated to account on average
for 5674 admissions to hospital (including nosocomial
infections) and 26 772 ambulatory visits among children aged
under 7 from 2000 to 2006 (including visits to general
practitioners and paediatricians).9
To reduce the burden of rotavirus disease, the World Health
Organization recommends inclusion of rotavirus vaccines into
all national immunisation programmes.10 Two oral rotavirus
vaccines are now available worldwide, a monovalent human
rotavirus vaccine (Rotarix; GlaxoSmithKline Biologicals,
Rixensart, Belgium) and a pentavalent bovine-human reassortant
rotavirus vaccine (RotaTeq; Merck, Whitehouse Station, NJ).
Both vaccines are highly efficacious for the prevention of
rotavirus gastroenteritis in large scale clinical trials.11-17 These
data suggest that vaccination has the potential to significantly
reduce the global burden of rotavirus disease. It is essential,
however, to establish the effectiveness of the vaccine under
conditions of routine use. The effectiveness of rotavirus vaccine
during routine use has been reported mainly in low-middle
income settings.18 19
Belgium was the first country in the European Union to include
rotavirus vaccine in the routine infant vaccination schedule,20
with rotavirus vaccination recommended since October 2006
and partially reimbursed since November 2006, resulting in a
copayment by the parents of €10 (about £8 or $12) per dose.
Uptake in Belgium has been rapid, with coverage rates already
over 90%.20 Modelling estimates suggest that a fully funded
universal rotavirus vaccination programme in Belgium with
uptake rates similar to those for other routine infant vaccinations
could reduce the annual number of hospital admissions for
rotavirus gastroenteritis by as much as 87%.21
We undertook a case-control study to estimate the effectiveness
of rotavirus vaccination for the prevention of admission to
hospital for rotavirus gastroenteritis among young children in
Belgium. We also collected data on the burden of rotavirus
disease, distribution of rotavirus genotypes, and co-infections
with other common intestinal viruses.
Methods
Study design
This was a prospective, hospital based, multicentre, matched
case-control study. Hospitals with paediatric beds in Belgium
were invited at random (following a list generated by random
sampling without replacement with R Statistical software (R
Foundation for Statistical Computing, Vienna, 2005)). We
contacted 60 hospitals to obtain the anticipated 39 hospitals
willing to participate in this study, representing about a third of
all hospitals with paediatric beds in Belgium and 1073 of the
total 2787 paediatric beds. Reasons for refusal to take part
included lack of time, lack of qualified personnel, closure of
the paediatric ward, and patient population not suitable for aim
of the study. Study design was based on the WHO generic
protocol for monitoring the impact of rotavirus vaccination on
the burden of gastroenteritis disease.22
Participants
Cases
We identified cases of gastroenteritis among children eligible
to have received at least one dose of any rotavirus vaccine (that
is, aged at least 14 weeks of age and born after 1 October 2006).
We reviewed admission logs to identify those with onset within
14 days of admission to hospital to determine eligibility for
inclusion in the study. Gastroenteritis was defined as at least
two episodes of vomiting or three episodes of diarrhoea, or both,
within a 24 hour period that were not because of an underlying
medical condition and that required at least one overnight stay
with oral or intravenous rehydration (equivalent to WHO plan
B or C). Stool samples were collected from eligible children
within 48 hours of admission and tested for the presence of
rotavirus with a rapid test (Rotastrip or Combistrip; Coris
BioConcept, Wepion, Belgium). Samples with positive results
for rotavirus by rapid test were stored at 2-8°C and sent to the
Laboratory of Clinical and Epidemiological Virology at the
University of Leuven for confirmation and genetic
characterisation of rotavirus infection by polymerase chain
reaction followed by sequencing. Samples confirmed to be
positive for rotavirus by polymerase chain reaction were also
tested for the presence of other common intestinal viruses
(adenovirus, astrovirus, and norovirus).
Children were not considered for inclusion in the study if they
had previously participated, if they had nosocomial
gastroenteritis, or if they had a condition where rotavirus
vaccination was contraindicated (including hypersensitivity to
active substance or any of the excipients of the rotavirus
vaccines, hypersensitivity after previous administration of
rotavirus vaccines, previous history of intussusception,
uncorrected congenital malformation of the gastrointestinal tract
that would predispose for intussusception, known or suspected
immunodeficiency, malignancies, receipt of immunosuppressive
treatment).
Controls
For each child with rotavirus gastroenteritis confirmed by
polymerase chain reaction, we identified one at least control
child who matched the case by date of birth (up to a maximum
of six weeks before or after) and was admitted to or was
attending an outpatient clinic at the same hospital for any reason
except gastroenteritis during the same time period. Eligible
controls were listed according to the date of admission/attending
date and participation was requested in chronological order.
Children were not considered for inclusion in the study if they
had previously participated, if they had symptoms of nosocomial
gastroenteritis, or if they had a condition where rotavirus
vaccination was contraindicated.
Data collection
For all children we interviewed parents and reviewed medical
records to obtain information on demographics, medical history
(including previous admission for gastroenteritis), current
feeding practice, socioeconomic status, and the current episode
of gastroenteritis (cases only). All reasonable efforts (several
phone calls or emails, including at least one letter by registered
mail) were made to confirm vaccination history (including the
brand of vaccine used, number of doses administered, and dates
of vaccination) from written sources—for instance, by
vaccination card or review of medical record.
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Sample size for vaccine effectiveness
Our primary analysis assessed the association between receipt
of two doses of monovalent rotavirus vaccine and admissions
to hospital for rotavirus gastroenteritis, therefore our precision
based sample size calculation was based on following
assumptions: rotavirus vaccine coverage rates in Belgium of
90%, with a market share for the monovalent rotavirus vaccine
of 80%; expected vaccine effectiveness of 80%; and an annual
background incidence rate of rotavirus in Belgium of 5000
admissions for rotavirus gastroenteritis in children aged under
6 years,23 with 50% of cases occurring in children under 1 year
and 38% of cases occurring in children aged 1-2 years. After
amendment of the case-control ratio from 2:1 to 1:1 (because
of difficulties in finding controls), we estimated that we needed
222 children admitted with rotavirus gastroenteritis confirmed
by polymerase chain reaction (and 222 age and hospital matched
controls) to provide 90% power, as initially planned, to show
the effectiveness of full series monovalent rotavirus vaccine
with a threshold of the lower limit of the two sided 95%
confidence interval equal to 50%. In addition, we assumed that
we would need to exclude 15% of confirmed cases from the
analysis (for example, because of the absence of age matched
controls), that 10% of children testing positive for rotavirus
with the rapid test would test negative by polymerase chain
reaction, and that rotavirus is responsible for about half of all
cases of gastroenteritis in the study population. We therefore
aimed to enrol 560 children with gastroenteritis.
Statistical analysis
Our primary objective was to estimate the effectiveness of the
full two dose course of the monovalent rotavirus vaccine for
the prevention of rotavirus gastroenteritis confirmed by
polymerase chain reaction and requiring admission to hospital
among age eligible children born after 1 October 2006 and aged
at least 14 weeks. The primary analysis of effectiveness included
only pairs in which the affected child (case) and the control had
received either two doses of the monovalent rotavirus vaccine
or no rotavirus vaccine at all and who met all criteria defined
in the protocol. When we derived the vaccination status for the
case and matched control(s), we considered only vaccine doses
administered at least 14 days before the onset date of
gastroenteritis.
We estimated vaccine effectiveness (%) as (1−matched odds
ratio of vaccination)×100. The matched odds ratio for
vaccination was calculated as a hazard ratio by using conditional
logistic regression with 95% confidence intervals. To identify
variables that could affect the estimate, we used models
controlling for factors potentially associated with vaccination
and rotavirus disease, including sex, attendance at day care,
attendance at preschool, medical history, history of breast
feeding, maternal education level, and household size. We
selected significant factors with a backward strategy, with
P<0.20 leading to retention in the model. Vaccine effectiveness
of the full two dose course of the monovalent rotavirus vaccine
was also estimated according to age at onset of disease (3-11
months and ≥12 months; for controls, age was computed at the
date of onset of disease of the matched case), severity of
rotavirus gastroenteritis determined with the Vesikari scale
(calculated with data available up to the visit and not for the
full duration of the episode of gastroenteritis),24 rotavirus
genotype, and the presence of common viral intestinal
co-infections. A Vesikari score of 1-10 was considered to
indicate mild or moderate disease, while a score of 11 or greater
was indicated severe disease (see appendix).24We also estimated
the effectiveness of at least one dose of any rotavirus vaccine
(intention to vaccinate analysis). For all estimates of vaccine
effectiveness, we performed a sensitivity analysis, assuming
that cases and controls with missing or unknown history of
vaccination were, respectively, vaccinated and unvaccinated
(sensitivity −), or vice versa (sensitivity +). Demographic
characteristics of cases and the controls were compared with
Fisher’s exact test for categorical variables and Student’s t test
for continuous variables. P<0.05 was considered significant.
As a secondary objective, we calculated the proportion of
admissions for gastroenteritis and the proportion of admissions
attributable to rotavirus infection among age eligible children
with exact 95% confidence intervals.
All statistical analyses were performed with SAS statistical
software (version 9.1, SAS, Cary, NC).
Results
Study population
Between February 2008 and June 2010, a total of 4742 age
eligible children admitted for gastroenteritis were screened for
inclusion in the study (fig 1⇓). We enrolled 554 children with
gastroenteritis (cases) and 352 controls. Of these, 215 cases and
276 controls were eligible for inclusion in the ATP (according
to protocol) confirmed cohort for analysis of vaccine
effectiveness (61 cases had two matched controls). Of the 276
controls, 53% (n=147) were admitted to hospital. The absolute
median difference between date of birth in cases and matched
controls was two weeks (range zero to six weeks). The absolute
median time difference between the date of admission in cases
and the admission/attending date of matched controls was five
weeks (range zero to 100 weeks).
Table 1 shows the demographic characteristics of the “according
to protocol” confirmed cohort (cases and controls)⇓. Median
age at enrolment was 12 months (range 3-31 months) for cases
and 15 months (3-39 months) for controls. This apparent
difference was caused by a time lag in the enrolment of controls.
The age of cases and controls at the onset of disease of the
matched case, however, was similar, indicating that the age
matching was successful (table 1). No significant differences
were seen between cases and controls in terms of previous
admission for gastroenteritis, medical history, or attendance at
day care (table 2⇓). Compared with controls, however, in cases
children were more commonly formula fed, came from a larger
size household, hadmothers with a lower education level (proxy
for socioeconomic status), and were less likely to attend
preschool. Concerning current feeding practice, only 4% of
controls and 2% of cases were breast fed and differences
regarding formula feeding are probably explained by the age
difference (at enrolment) between cases and controls.
We were able to review written sources to validate history of
rotavirus vaccination for 92% (n=197) of cases and 90% (n=249)
of controls. There was a significant difference between cases
and controls with respect to vaccination history, with 48%
(n=99) of cases and 91% (n=244) of controls having received
at least one dose of any rotavirus vaccine (P<0.001). This
difference was observed in all age groups. The monovalent
vaccine was the most commonly used rotavirus vaccine,
accounting for 92% (n=594) of all rotavirus vaccine doses (95%
(n=176) for cases and 90% (n=418) for controls). Most children
who had received the monovalent rotavirus vaccine had
completed the full two dose schedule (95%, 281/296).
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Burden of rotavirus disease and clinical
presentation
Of the 46 856 admissions to hospital among age eligible children
in the participating hospitals during the study period, 4742 (10%)
were for gastroenteritis. Of the 4138 screened children admitted
with gastroenteritis who provided stool samples for rapid testing,
655 (16%) had positive results for rotavirus (fig 2⇓). Of the 255
cases with a positive rapid test result and available result from
polymerase chain reaction, 248 (97%) were confirmed positive
for rotavirus. The peak proportion of admissions for
gastroenteritis attributable to rotavirus seemed to decrease with
each rotavirus season during the study period, from 39% in
March 2008 to 35% in March 2010.
For the 215 confirmed cases included in the ATP confirmed
cohort, the most commonly reported symptoms were vomiting
(89%, n=190), diarrhoea (88%, n=189), behaviour change (80%,
n=156), and fever (80%, n=171). No differences were seen in
terms of presence/absence of different signs/symptoms between
the children (cases) who had received both doses of the
monovalent rotavirus vaccine and those who had not been
vaccinated (table 3⇓). In terms of disease severity, the Vesikari
score could not be measured for 25% of all participants (cases
and controls) because of one or several missing answers in the
different elements needed to calculate the score. Among the
remaining participants, 67% (n=40) of cases who had received
both doses of the monovalent rotavirus vaccine were classified
as “severe” according to the Vesikari score (score ≥11 points)
compared with 86% (n=69) of cases in the unvaccinated
participants. Unvaccinated participants tended to be more
dehydrated.We performed a sensitivity analysis (see appendix)
with worst or best case scenario for the missing elements, which
showed similar results. We found no difference in terms of
treatment patterns between the two groups (table 3⇓). Only one
case in each group required treatment in an intensive care unit.
Median duration of admission was four days (range zero to 12
days) and five days (two to eight days) in the two groups,
respectively.
Effectiveness of rotavirus vaccination
For the primary analysis, we included in the logistic regression
analysis only informative case-control pairs in terms of
vaccination status with the monovalent rotavirus vaccine (that
is, case fully vaccinated or an unvaccinated case and at least
one control fully vaccinated or an unvaccinated control).
Therefore we included 160 pairs (70 fully vaccinated and 90
unvaccinated cases with their 179 fully vaccinated and 19
unvaccinated matched controls). Effectiveness of two doses of
themonovalent rotavirus vaccine for the prevention of admission
for rotavirus gastroenteritis was 90% (95% confidence interval
81% to 95%; table 4⇓). Results of the sensitivity analysis for
this primary objective ranged from 76% to 93%. The
effectiveness of two doses of the monovalent rotavirus vaccine
was 91% (75% to 97%) in children aged 3-11 months, and 90%
(76% to 96%) in those aged ≥12 months. After adjustment for
potential confounding factors in the conditional logistic
regression model (table 5⇓), the effectiveness of two doses of
themonovalent rotavirus vaccine against admission for rotavirus
gastroenteritis was 90% (79% to 96%) overall.
In the intention to vaccinate analysis, the effectiveness of at
least one dose of any rotavirus vaccine against admission for
rotavirus gastroenteritis was 91% (82% to 95%). The
effectiveness of at least one dose of any rotavirus vaccine was
93% (80% to 97%) in children aged 3-11months and 89% (75%
to 95%) in those aged 12 months or older.
In all, 56% (n=120) of cases of rotavirus gastroenteritis were
classified as severe according to the Vesikari scale (score ≥11
points). The effectiveness of two doses of the monovalent
rotavirus vaccine against severe rotavirus gastroenteritis was
91% (80% to 96%). Vaccine effectiveness was 66% (−31% to
91%) against rotavirus gastroenteritis of mild to moderate
severity according to the Vesikari scale (score 1-10 points). The
difference in vaccine effectiveness according to severity of
gastroenteritis was not significant.
Of all cases of rotavirus gastroenteritis confirmed by polymerase
chain reaction in the ATP confirmed cohort, 52% (n=111) were
G2P[4], 24% (n=52) were G1P[8], 9% (n=20) were G4P[8],
7% (n=16) were G3P[8], and 5% (n=11) were G9P[8]. No other
genotype accounted for more than one case. The effectiveness
of two doses of themonovalent rotavirus vaccine was 85% (64%
to 94%) against G2P[4] and 95% (78% to 99%) against G1P[8].
These estimates were calculated without adjustment for potential
confounding factors.
Co-infection with one or more of the following intestinal viruses
was observed in a quarter (n=53) of cases of rotavirus
gastroenteritis confirmed by polymerase chain reaction in the
ATP confirmed cohort: astrovirus (n=29, 13%), adenovirus
(n=29, 13%), and norovirus (n=2, 1%). The effectiveness of
two doses of themonovalent rotavirus vaccine against admission
for rotavirus gastroenteritis with viral co-infection was 86%
(52% to 96%). These estimates were calculated without
adjustment for potential confounding factors.
Discussion
This case-control study showed that rotavirus vaccination is
effective for the prevention of admission to hospital for rotavirus
gastroenteritis among young children in Belgium, despite the
high prevalence of G2P[4] strains and a high rate of co-infection
with other common intestinal viruses. Results of an intention
to vaccinate analysis showed that at least one dose of any
rotavirus vaccine can provide 91% protection against hospital
admission. Estimates of vaccine effectiveness were robust, as
indicated by the results of sensitivity analyses and after
adjustment for potential confounding factors in the conditional
logistic regression model.
With rotavirus vaccines increasingly being introduced into
childhood immunisation programmes, monitoring effectiveness
in real life settings is a high priority. The European Medicines
Agency required evidence of field effectiveness after the
introduction of the vaccine. In Latin America, the US, Europe,
and Australia considerable reductions in rotavirus infections
and related admissions among young children have been
reported after introduction of rotavirus vaccine,25-36 with
vaccination associated with a significant decline in overall deaths
related to diarrhoea among children aged under 5 in Mexico.37
Such observational studies, however, were uncontrolled and
potentially biased.
Comparison with other studies
Our estimates of vaccine effectiveness are comparable with the
reported efficacy of both currently available rotavirus vaccines
in large scale prelicensing clinical trials11-17 and similar to
estimates of the effectiveness of the pentavalent rotavirus
vaccine observed in case-control studies undertaken in the
US.38 39 Estimates of effectiveness of vaccine in our study were
higher than have been reported in lower income settings, with
the effectiveness of two doses of the monovalent rotavirus
vaccine against admission for rotavirus gastroenteritis being
76% in El Salvador and Brazil18 19 and an overall efficacy of the
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monovalent rotavirus vaccine in preventing episodes of severe
rotavirus gastroenteritis of 61% in a clinical trial that was
designed to simulate real world conditions of use in Malawi
and South Africa.40 Research is mandatory to clearly identify
the reasons for this lower potency in these challenging target
countries. Micronutrient malnutrition, environmental factors,
differences in the epidemiology of the virus, breast feeding at
the time of vaccination, and underlying medical conditions
might negatively affect the immunity of the children and
performance of the monovalent vaccine.41 42
In contrast with results of case-control studies in Latin America
and Central Australia that have suggested that vaccine
effectiveness might decrease slightly during the second year of
life,18 19 43-45 we found no difference in effectiveness between
children aged 3-11 months and those aged 12 months or older.
Duration of protection is an important factor influencing the
potential public health impact of rotavirus vaccines.
As observed in other case-control studies,18 19 we found
vaccination to confer greatest protection against severe disease
(that is, children with scores of 11 or more on the Vesikari
scale). In the present study, 44% of cases of rotavirus
gastroenteritis were considered to be mild to moderate in
severity according to the Vesikari scale. This was somewhat
unexpected in a hospital setting. Almost all affected children
required intravenous rehydration (84%). The Vesikari scale
assigns points according to the duration and severity of diarrhoea
and vomiting, degree of fever, presence of dehydration, and
treatment given (oral or intravenous rehydration).24 In this study,
however, we calculated Vesikari score using only data available
up to the visit and not for the full duration of the episode of
gastroenteritis, therefore wemight have slightly underestimated
severity of cases as the duration of symptoms would probably
have been longer.
In line with other studies,19 43we found that vaccination provided
effective protection against G2P[4] strains, which accounted
for over half of all cases of rotavirus gastroenteritis in the present
study. Cross protection is an important feature for rotavirus
vaccines, considering the global strain diversity. Especially in
Africa, the vaccines will need to confer protection against a
wide variety of strain types, therefore it is essential to assess
effectiveness in these settings.46 We found evidence of
co-infections with adenovirus, astrovirus, or norovirus in a
quarter of all cases in this study, but these viral co-infections
did not impact on vaccine effectiveness. Limited data are
available on co-infection rates in rotavirus gastroenteritis, though
the rate we observed in this study is higher than other recent
reports. Mixed viral intestinal infections including rotavirus
were reported in 13% of paediatric admission for gastroenteritis
in a recent Italian study47 and in only 3.3% of children admitted
for gastroenteritis in a study in northern France.48
In terms of disease burden, we found rotavirus to be responsible
for about 16% of admissions for gastroenteritis among young
children in Belgium. Surveillance undertaken in Belgium before
introduction of rotavirus vaccine found that rotavirus
gastroenteritis accounted for 58% of admission for
gastroenteritis in this age group.6 The potential public health
impact of rotavirus vaccination in Belgium under the current
settings (that is, effectiveness of two doses of the monovalent
rotavirus vaccine of 90% and 90% coverage rate) can be
estimated at 4596 avoided admissions a year among children
aged under 7. Our findings are in line with the reported reduction
in the number of admissions attributable to rotavirus
gastroenteritis in a regional Belgian hospital that was not
selected for participation in this study29 and with the reduction
in the number of laboratory confirmed cases of rotavirus
gastroenteritis observed in Belgium after vaccine introduction.31
The proportion of admissions for rotavirus gastroenteritis in
infants aged 3-5 months in our study (6.6%) was similar to that
reported in Europe before introduction of the rotavirus
vaccine.4 7 8 These findings highlight that a small but still
considerable absolute number of young infants acquire rotavirus
gastroenteritis, highlighting the need for a vaccine that can
provide early protection against infection.
Strengths and limitations of the study
We estimated the field effectiveness of rotavirus vaccines in a
post-marketing setting using a robust case-control design and
investigated the potential impact of common viral intestinal
co-infections on effectiveness of the vaccine. The study covered
a third of all hospitals with paediatric beds in Belgium, with a
common protocol, identical case definitions, and the same
laboratory diagnostic methods across all participating sites. A
further study strength is that nearly all vaccinated children
received one type of rotavirus vaccine, which simplifies
interpretation of study findings; the monovalent rotavirus
vaccine accounted for 92% of all administered doses.
Although case-control studies are recognised as an effective
method of assessing vaccine effectiveness in routine clinical
practice,22 selection bias and other issues need to be considered
in the interpretation of estimates of effectiveness.
One major concern is that ideally controls should represent the
source population to which cases belong. Controls werematched
by date of birth and hospital, thereby minimising the
confounding bias by these factors. Although we determined that
one major socioeconomic factor (number of bedrooms) was
similar between cases and controls, there were significant
differences in some demographic and socioeconomic variables
between the two study groups, which could potentially affect
effectiveness of the vaccine. We attempted to control for some
of these factors in the multivariate analysis, which resulted in
similar estimates of effectiveness.
The larger household size for cases compared with controls
could also have resulted in increased rates of transmission of
rotavirus in the households of affected children. Results of recent
primary care based surveillance undertaken to estimate the
burden of rotavirus gastroenteritis among children aged under
5 years in six European countries highlighted the high likelihood
of transmission of rotavirus among young children within the
home.8 The fact that affected children were more commonly
formula fed might also have influenced the risk of developing
rotavirus gastroenteritis. A recent community based study
involving 30 paediatric practices in Germany, Switzerland, and
Austria suggested that breast feedingmight protect young infants
against rotavirus gastroenteritis.49 As only 4% of controls and
2% of affected children were being breast fed, differences
regarding formula feeding are probably explained by the age
difference between cases and controls. Estimates of vaccine
effectiveness adjusted to account for such differences between
groups, however, were not significantly different to those
obtained in the primary unadjusted analysis. Nevertheless, the
smaller household size, the higher educational status of mothers,
and the higher preschool attendance in the control group could
suggest socioeconomic inequities in uptake of rotavirus vaccine
(especially in a setting with partial reimbursement). These
observed differences suggest that further research into possible
socioeconomic inequality in access to vaccination might be
warranted.
Another inherent limitation of observational studies is the
possibility that the obtained history of rotavirus vaccination
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might not be correct. Rotavirus vaccination, however, is the
only oral vaccine administered in Belgium, making it more
easily remembered by parents. Furthermore, registration of
vaccination is common practice in well baby clinics, general
practitioner clinics, and other paediatric settings in Belgium,
thereby reducing the chance of missing vaccination, and we
reviewed written sources of vaccination history for most study
participants (92% of cases and 90% of controls). Moreover,
there is an equal risk of misclassification for cases and controls
and, as controls already had a high reported vaccine uptake
(>90%), this possible underestimate is probably minimal and
will have little effect on the estimates of effectiveness as
currently calculated.
It is unlikely that paediatricians might have included children
with a higher chance of being vaccinated as a control. While
logistical reasons prevented us from blinding the interviewers
to knowledge of case and control status, identification and
enrolment of the cases was not done by the same person who
verified the vaccination status. Moreover, recent data show high
coverage rates for vaccines implemented in the national
childhood immunisation programme (for example, at least 98%
of infants received three doses of the diphtheria-tetanus-pertussis
vaccine) and therefore indicate that there are few barriers for
vaccination in Belgium.50-52
Finally, although a third of all paediatric departments in Belgium
were included as study sites, these cases might not represent
the full spectrum of severe rotavirus gastroenteritis cases in the
population in Belgium.
Conclusions and policy implications
Currently available rotavirus vaccines are highly effective for
the prevention of hospital admissions for rotavirus gastroenteritis
among young children in Belgium under conditions of routine
use. Our findings should prove useful for public health officers
and policy makers to encourage implementation of rotavirus
vaccine use in other similar high income countries.
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Tables
Table 1| Demographic characteristics in all children with rotavirus confirmed by polymerase chain reaction and having at least one valid
control (according to protocol, confirmed cohort) and matched controls. Figures are numbers (percentage) unless stated otherwise
Controls (n=276)Children with rotavirus (n=215)Characteristic
Age at onset* (months):
12.613.0Mean
12 (2-31)11 (2-31)Median (range)







*For controls, age is computed at date of onset of disease in matched case.
†Age at onset could be lower than 3 months given that inclusion criteria were “at least 14 weeks of age at time of hospital admission” and “onset of severe
gastroenteritis ≤14 days before admission.” Two children <3 months were exactly 89 days old (for case) and 81 days old (for control).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012; 2012:345:e4752:e4752 doi: 10.1136/bmj.e4752 (Published 8 August 2012) Page 8 of 13
RESEARCH
Table 2| Clinical and socioeconomic characteristics in all children with rotavirus confirmed by polymerase chain reaction and having at
least one valid control (according to protocol, confirmed cohort) andmatched controls. Figures are numbers (percentages) unless otherwise
stated
P valueControls (n=276)Children with rotavirus (n=215)Characteristic
0.2924 (9)25 (12)Previous admission to hospital for gastroenteritis
Medical history:
0.6023 (9)14 (7)Premature birth
1.006 (2)4 (2)Cardiac disease
0.8149 (18)35 (17)Pulmonary disease
0.2138 (14)21 (10)Gastrointestinal disease
0.3557 (21)36 (17)Other
Current feeding practice*:
0.2012 (4)4 (2)Breast fed
0.003105 (38)112 (52)Formula fed
0.65250 (901)192 (89)Solid food
Highest level of maternal education†:
0.00390 (0.0)1 (0.5)None
2 (0.8)10 (5)Primary school
101 (38)96 (46)Secondary school
113 (43)67 (32)Higher education (≤3 years)
48 (18)33 (16)Higher education (>3 years)
0.292.9 (0.9)3.0 (1.3)Mean (SD) No of bedrooms in home
<0.0013.6 (0.8)4.2 (2)Mean (SD) No of people spending >3 nights/week in home
0.64116 (62)125 (60)Daycare attendance
<0.00121 (8)1 (0.5)Preschool attendance
*Children can be included in more than one category.
†As proxy for socioeconomic status.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012; 2012:345:e4752:e4752 doi: 10.1136/bmj.e4752 (Published 8 August 2012) Page 9 of 13
RESEARCH
Table 3| Clinical characteristics and management of rotavirus gastroenteritis in children who had received both doses of monovalent
rotavirus vaccines (vaccinated cases) and those who had not received any rotavirus vaccination (unvaccinated cases) in children with
rotavirus confirmed by polymerase chain reaction and having at least one valid control (according to protocol, confirmed cohort). Figures
numbers (percentages) unless otherwise stated
Unvaccinated† (n=108)Fully vaccinated*(n=83)




880 (80)959 (80)Behaviour change
285 (80)065 (78)Fever
Severity (Vesikari scale)24:
2811 (14)2320 (33)Mild/moderate (1-10)
69 (86)40 (67)Severe (≥11)
Treatment received:
276 (72)165 (79)Oral rehydration
289 (84)070 (84)Intravenous rehydration
21 (0.9)11 (1.2)Intensive care
Duration of admission (days):
05 (2-8)04 (1-12)Median (range)
4.5 (1.4)4.6 (1.9)Mean (SD)
*Children who had received both doses of monovalent rotavirus vaccine (information regarding two children partially vaccinated with monovalent rotavirus vaccine,
three children vaccinated with three doses of pentavalent rotavirus vaccine (n=3), those in category “other” (n=11), and those in category “unknown” (n=8) is not
shown).
†Children who had not received any rotavirus vaccination.
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Table 4| Effectiveness of human rotavirus vaccine against admission to hospital for rotavirus gastroenteritis (Belgium, February 2008-June
2010) in all children with rotavirus confirmed by polymerase chain reaction and having at least one valid control (according to protocol,
confirmed cohort) and matched controls. Estimates of effectiveness are not adjusted for potential confounding variables
Sensitivity (%)*Vaccine effectiveness (%
(95% CI))
No/total receiving vaccine
+–Matched controlsChildren with rotavirus
Received two doses of monovalent vaccine
937690 (81 to 95)179/19870/160Overall
Age (months):
946991 (75 to 97)79/8430/663-11
918290 (76 to 96)100/11440/94≥12
Co-infection status:
937891 (81 to 96)134/14850/121Not co-infected
906986 (52 to 96)45/5020/39Co-infected
Genotype†:
959295 (78 to 99)49/5311/41G1P[8]
895485 (64 to 94)93/10346/80G2P[4]
Severity (Vesikari scale)‡:
73866 (–31 to 91)28/3416/26Mild/moderate (1-10)
938891 (80 to 96)110/12138/96Severe (≥11)
Received at least one dose of any rotavirus vaccine
937891 (82 to 95)208/22881/179Overall
By age (months):
957593 (80 to 97)99/10436/773-11
908189 (75 to 95)109/12445/102≥12
*Sensitivity–: cases and controls with other or unknown vaccination status are assumed, respectively, to be vaccinated and unvaccinated; sensitivity +: cases and
controls with other or unknown vaccination status are assumed, respectively, to be unvaccinated and vaccinated
†Only effectiveness results for pairs in which case had either genotype G1P[8] or G2P[4] could be estimated, as for other genotypes numbers were too small.
‡Severity missing for 38 cases (matched to 43 controls).
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Table 5| Estimated coefficients of final fitted logistic regression model for effectiveness of two doses of monovalent rotavirus vaccine
against admission to hospital for rotavirus gastroenteritis (Belgium, February 2008-June 2010) in all children with rotavirus confirmed by
polymerase chain reaction and having at least one valid control (according to protocol, confirmed cohort) and matched controls
Adjusted odds ratio (95% CI)P valueNo (%) of controls (n=182)
No (%) of children with
rotavirus (n=145)*Parameter
——17 (9)79 (54)Not vaccinated (reference)
0.10 (0.05 to 0.21)<0.001165 (91)66 (46)Two doses of monovalent rotavirus
vaccine
0.51 (0.19 to 1.39)0.188——Gastrointestinal diseases (yes v no†)
0.45 (0.16 to 1.21)0.112——Pulmonary disease (yes v no†)
1.40 (1.00 to 1.94)0.048——Household size‡
*Because logistic regression model requires complete data, 15 (15 cases and their 16 matched controls) out of 160 pairs available for primary analysis were
excluded because of missing information for at least one of variables included in model.
†Reference category.
‡Number of people sleeping in house for more than three nights a week.
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Figures
Fig 1 Summary of enrolment by cohort. Screened cohort=all children aged ≥14 weeks and born after 1 October 2006
admitted with gastroenteritis. Total enrolled cohort=all children (cases and controls) for whom informed consent was obtained.
ATP enrolled cohort=all valid enrolled cases and controls. ATP confirmed cohort=all valid cases confirmed by polymerase
chain reaction with at least one valid control and their matched controls (used for analyses of vaccine effectiveness); (154
cases have 1 matched control, 61 cases have 2 matched controls)
Fig 2 Number of admissions attributable to gastroenteritis and rotavirus gastroenteritis (in according to protocol (ATP)
enrolled cohort)
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